Application 206957
- Type
- ANDA
- Sponsor
- MYLAN
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TADALAFIL | TADALAFIL | TABLET;ORAL | 5MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A206957-001 | TADALAFIL | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A206957-001 | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A206957-001 | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A206957-001 | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A206957-001 | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A206957-001 | TADALAFIL | 5MG | TABLET / ORAL | 2019-04-29 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A206957-001 | AB | 1 | 74a2ff9319b5… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A206957-001 | AB1 | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A206957-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A206957-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A206957-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A206957-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A206957-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A206957-001 | AB | 1 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 6c680b37-d515-4fc2-83e6-411f1017e18c | 2026-11-03 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | e899da81-a28e-4a7e-a0e6-ed6d557c0bcd | 2026-11-02 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 828f0ee1-b9fc-4743-9394-fc086bcf5345 | 2026-11-02 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 5de70f00-00ac-4656-883e-d1e07d5f71d6 | 2026-10-29 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| tadalafil | TADALAFIL | REMEDYREPACK INC. | b927f04e-63d2-4d3d-bc07-93d85f5a29c6 | 2026-10-28 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| tadalafil | TADALAFIL | PD-RX Pharmaceuticals, Inc. | fc7596dd-42d3-af7c-e053-6294a90af01e | 2026-10-28 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | NIVAGEN PHARMACEUTICALS, INC. | ca1d46e3-ad9b-48c7-bb7f-63ee678ccf7a | 2026-10-26 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Umedica Laboratories USA Inc. | 6caf3b55-9bf4-4355-9e25-8bf368943fdd | 2026-10-23 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | NorthStar Rx, LLC | a10d464a-6ea7-4e5a-befa-71eceacc5039 | 2026-10-23 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| tadalafil | TADALAFIL | Bryant Ranch Prepack | 91945e16-9499-45c1-bd62-fc064acfed5e | 2026-10-15 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| TADALAFIL | TADALAFIL | Preferred Pharmaceuticals Inc. | 66e24ced-0008-40cb-b242-9d9add1f665c | 2026-10-09 | Warnings, Adverse reactions | TADALAFIL TADALAFIL |
| TADALAFIL | TADALAFIL | Preferred Pharmaceuticals Inc. | 09ad27a1-3908-4533-b84c-7a7fd3514101 | 2026-09-28 | Warnings, Adverse reactions | TADALAFIL TADALAFIL |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 2354c3e2-7b5f-4fdd-bbf2-7fa3c57686f8 | 2026-09-25 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 761dc0f8-2f65-4615-ab49-a4bcffd40ce9 | 2026-09-25 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | REMEDYREPACK INC. | ad288e9d-020a-43a0-9c07-320c5c3bbc1e | 2026-09-16 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | A-S Medication Solutions | b1840f16-a7ea-44bd-b091-5268990aedb2 | 2026-09-09 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | A-S Medication Solutions | 81222924-29d9-4031-954d-132923867b8e | 2026-09-09 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | A-S Medication Solutions | cf9431ef-ea02-457d-b83a-ce13fb963d95 | 2026-08-28 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
| tadalafil | TADALAFIL | Bryant Ranch Prepack | 394be6ef-c0f7-4cd5-8062-39fda5c1c2c4 | 2026-08-27 | Warnings, Adverse reactions | tadalafil TADALAFIL |
| Tadalafil | TADALAFIL | A-S Medication Solutions | a6847ad6-3b5b-47e5-a3b5-04dc3182d72b | 2026-08-25 | Warnings, Adverse reactions | Tadalafil TADALAFIL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.